Shares of biopharmaceutical company Liquidia Corporation (LQDA) were rising more than 12 percent in pre-market on Monday to $14.45, after the U.S. district court denied United Therapeutics' request to block the launch of Liquidia's Yutrepia inhalation powder to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).
"The ruling reinforces the clear path for the U.S. Food and Drug Administration to issue a final decision on the amended New Drug Application for Yutrepia," Liquidia said in a statement.
Liquidia shares had closed at $12.87, up 0.08 percent on Friday. The stock has been trading in the range of $5.71 - $16.99 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.